Ikena Oncology Inc
NASDAQ:IKNA

Watchlist Manager
Ikena Oncology Inc Logo
Ikena Oncology Inc
NASDAQ:IKNA
Watchlist
Price: 17.16 USD 4.38% Market Closed
Market Cap: 2.1B USD

Relative Value

There is not enough data to reliably calculate the relative value of IKNA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IKNA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
9
Median 3Y
282.2
Median 5Y
295.4
Industry
2.6
vs History
vs Industry
Median 3Y
-41.7
Median 5Y
-73.7
Industry
21.4
Forward
-310.2
vs History
vs Industry
Median 3Y
-44.6
Median 5Y
-52.7
Industry
16.4
vs History
vs Industry
Median 3Y
-44.6
Median 5Y
-51.8
Industry
22.8
vs History
70
vs Industry
73
Median 3Y
16.7
Median 5Y
24.4
Industry
2.2
vs History
vs Industry
78
Median 3Y
274.3
Median 5Y
281.9
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
53
Median 3Y
-35.7
Median 5Y
-66.9
Industry
13
Forward
-21.2
vs History
vs Industry
50
Median 3Y
-35.3
Median 5Y
-68.5
Industry
16.5
Forward
-57.5
vs History
vs Industry
53
Median 3Y
-41.9
Median 5Y
-50.4
Industry
15.6
vs History
vs Industry
40
Median 3Y
-41.9
Median 5Y
-49.3
Industry
18.7
vs History
78
vs Industry
62
Median 3Y
176.1
Median 5Y
268.4
Industry
1.9

Multiples Across Competitors

IKNA Competitors Multiples
Ikena Oncology Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Ikena Oncology Inc
NASDAQ:IKNA
2.1B USD 0 -41.7 -35.6 -35.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.3 55.7 37.4 40.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
495.1B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
270.3B CHF 4.4 28.7 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
219.8B GBP 5.1 31.4 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
276.1B USD 4.3 14.5 10.3 12.2
CH
Novartis AG
SIX:NOVN
218.3B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.8 11 12.8
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.8B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
US
Ikena Oncology Inc
NASDAQ:IKNA
Average P/E: 24.9
Negative Multiple: -41.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
3%
5.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Ikena Oncology Inc
NASDAQ:IKNA
Average EV/EBITDA: 440
Negative Multiple: -35.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.4
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Ikena Oncology Inc
NASDAQ:IKNA
Average EV/EBIT: 1 883.7
Negative Multiple: -35.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.1
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5